LncRNA AC142119.1 Facilitates the Progression of Neuroblastoma by Epigenetically Initiating the Transcription of MYCN

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2023 Sep 23

PMID 37741985

Authors

Rui Yang

Nanjing Liu

Ting Li

Fangjie Liu

Jun Zhang

Hui Zhao

Lin Zou

Xiaoyan He

Affiliations

Soon will be listed here.

Abstract

Background: Oncogene MYCN is closely related with malignant progression and poor prognosis of neuroblastoma (NB). Recently, long non-coding RNAs (lncRNAs) have been recognized as crucial regulators in various cancers. However, whether lncRNAs contribute to the overexpression of MYCN in NB is unclear.

Methods: Microarray analysis were applied to analyze the differentially expressed lncRNAs between MYCN-amplified and MYCN-non-amplified NB cell lines. Bioinformatic analyses were utilized to identify lncRNAs nearby MYCN locus. qRT-PCR was used to detect the expression level of lncRNA AC142119.1 in NB cell lines and tissues. Gain- and loss-of-function assays were conducted to investigate the biological effect of AC142119.1 in NB. Fluorescence in situ hybridization, RNA pull-down, RNA immunoprecipitation, mass spectrometry, RNA electrophoretic mobility shift, chromatin immunoprecipitation and chromatin isolation by RNA purification assays were performed to validate the interaction between AC142119.1 and WDR5 protein as well as MYCN promoter.

Results: AC142119.1 was significantly elevated in NB tissues with MYCN amplification, advanced INSS stage and high risk, and associated with poor survival of NB patients. Moreover, enforced expression of AC142119.1 reinforced the proliferation of NB cells in vitro and in vivo. Additionally, AC142119.1 specifically recruited WDR5 protein to interact with MYCN promoter, further initiating the transcription of MYCN and accelerating NB progression.

Conclusions: We identified a novel lncRNA AC142119.1, which promoted the progression of NB through epigenetically initiating the transcription of MYCN via interacting with both WDR5 protein and the promoter of MYCN, indicating that AC142119.1 might be a potential diagnostic biomarker and therapeutic target for NB.

Citing Articles

NONHSAT141192.2 Facilitates the Stemness and Radioresistance of Glioma Stem Cells via the Regulation of PIK3R3 and SOX2.

Wang S, Ming H, Wang Z, Zhai X, Zhang X, Wu D CNS Neurosci Ther. 2025; 31(2):e70279.

PMID: 39968701 PMC: 11836614. DOI: 10.1111/cns.70279.

Highly expressed B3GALT5-AS1 contributes to gastric cancer progression by recruiting WDR5 to mediate B3GALT5 and regulating β-catenin/ZEB1 axis.

Feng W, Tang Y, Jing R, Ju S, Zong W J Cell Mol Med. 2024; 28(17):e70061.

PMID: 39224045 PMC: 11369489. DOI: 10.1111/jcmm.70061.

Long Non-Coding RNAs in Neuroblastoma: Pathogenesis, Biomarkers and Therapeutic Targets.

Vercouillie N, Ren Z, Terras E, Lammens T Int J Mol Sci. 2024; 25(11).

PMID: 38891878 PMC: 11171840. DOI: 10.3390/ijms25115690.

References

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

Han X, Huang S, Xue P, Fu J, Liu L, Zhang C . LncRNA modulates M2 macrophage activation and inflammatory diseases by epigenetic promotion of PTPRE. Sci Adv. 2019; 5(12):eaax9230. PMC: 6905863. DOI: 10.1126/sciadv.aax9230. View

Sun Y, Bell J, Carter D, Gherardi S, Poulos R, Milazzo G . WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. Cancer Res. 2015; 75(23):5143-54. DOI: 10.1158/0008-5472.CAN-15-0423. View

Zeineldin M, Patel A, Dyer M . Neuroblastoma: When differentiation goes awry. Neuron. 2022; 110(18):2916-2928. PMC: 9509448. DOI: 10.1016/j.neuron.2022.07.012. View

Liu X, Chen J, Zhang S, Liu X, Long X, Lan J . LINC00839 promotes colorectal cancer progression by recruiting RUVBL1/Tip60 complexes to activate NRF1. EMBO Rep. 2022; 23(9):e54128. PMC: 9442307. DOI: 10.15252/embr.202154128. View

Pinto N, Applebaum M, Volchenboum S, Matthay K, London W, Ambros P . Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015; 33(27):3008-17. PMC: 4567703. DOI: 10.1200/JCO.2014.59.4648. View

Winkle M, El-Daly S, Fabbri M, Calin G . Noncoding RNA therapeutics - challenges and potential solutions. Nat Rev Drug Discov. 2021; 20(8):629-651. PMC: 8212082. DOI: 10.1038/s41573-021-00219-z. View

Johnsen J, Dyberg C, Wickstrom M . Neuroblastoma-A Neural Crest Derived Embryonal Malignancy. Front Mol Neurosci. 2019; 12:9. PMC: 6361784. DOI: 10.3389/fnmol.2019.00009. View

Otte J, Dyberg C, Pepich A, Johnsen J . MYCN Function in Neuroblastoma Development. Front Oncol. 2021; 10:624079. PMC: 7873735. DOI: 10.3389/fonc.2020.624079. View

10.

Li Z, Liang N, Wang N, Jia Y, Tian C . WDR5 is a prognostic biomarker of brain metastasis from non-small cell lung cancer. Front Oncol. 2022; 12:1023776. PMC: 9557102. DOI: 10.3389/fonc.2022.1023776. View

11.

Fetahu I, Taschner-Mandl S . Neuroblastoma and the epigenome. Cancer Metastasis Rev. 2021; 40(1):173-189. PMC: 7897201. DOI: 10.1007/s10555-020-09946-y. View

12.

Verhoeven B, Mei S, Olsen T, Gustafsson K, Valind A, Lindstrom A . The immune cell atlas of human neuroblastoma. Cell Rep Med. 2022; 3(6):100657. PMC: 9245004. DOI: 10.1016/j.xcrm.2022.100657. View

13.

Luo M, Xie L, Su Y, Zhang K, Liang R, Ma Z . TM4SF19-AS1 facilitates the proliferation of lung squamous cell carcinoma by recruiting WDR5 to mediate TM4SF19. Mol Cell Probes. 2022; 65:101849. DOI: 10.1016/j.mcp.2022.101849. View

14.

Xie Q, Li Z, Chen J . WDR5 positively regulates p53 stability by inhibiting p53 ubiquitination. Biochem Biophys Res Commun. 2017; 487(2):333-338. DOI: 10.1016/j.bbrc.2017.04.060. View

15.

Olsen R, Otero J, Garcia-Lopez J, Wallace K, Finkelstein D, Rehg J . MYCN induces neuroblastoma in primary neural crest cells. Oncogene. 2017; 36(35):5075-5082. PMC: 5582212. DOI: 10.1038/onc.2017.128. View

16.

Westermark U, Wilhelm M, Frenzel A, Henriksson M . The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 2011; 21(4):256-66. DOI: 10.1016/j.semcancer.2011.08.001. View

17.

Liu X, Wang C, Liu W, Li J, Li C, Kou X . Distinct features of H3K4me3 and H3K27me3 chromatin domains in pre-implantation embryos. Nature. 2016; 537(7621):558-562. DOI: 10.1038/nature19362. View

18.

Nie Y, Zhou L, Wang H, Chen N, Jia L, Wang C . Profiling the epigenetic interplay of lncRNA RUNXOR and oncogenic RUNX1 in breast cancer cells by gene in situ cis-activation. Am J Cancer Res. 2019; 9(8):1635-1649. PMC: 6726995. View

19.

Song H, Li D, Wang X, Fang E, Yang F, Hu A . HNF4A-AS1/hnRNPU/CTCF axis as a therapeutic target for aerobic glycolysis and neuroblastoma progression. J Hematol Oncol. 2020; 13(1):24. PMC: 7098112. DOI: 10.1186/s13045-020-00857-7. View

20.

Lu C, Liu Z, Klement J, Yang D, Merting A, Poschel D . WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. J Immunother Cancer. 2021; 9(7). PMC: 8323468. DOI: 10.1136/jitc-2021-002624. View